Cargando…

Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)

BACKGROUND: In recent years, genetic factors have attracted research interest as important predisposing factors for cardiovascular susceptibility. This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shuxia, Zhang, Yi, Wang, Lili, Geng, Yanping, Gu, Jian, Hao, Qingqing, Wang, Hua, Qi, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555704/
https://www.ncbi.nlm.nih.gov/pubmed/28783717
http://dx.doi.org/10.12659/MSM.903054
_version_ 1783256962421489664
author Chen, Shuxia
Zhang, Yi
Wang, Lili
Geng, Yanping
Gu, Jian
Hao, Qingqing
Wang, Hua
Qi, Peng
author_facet Chen, Shuxia
Zhang, Yi
Wang, Lili
Geng, Yanping
Gu, Jian
Hao, Qingqing
Wang, Hua
Qi, Peng
author_sort Chen, Shuxia
collection PubMed
description BACKGROUND: In recent years, genetic factors have attracted research interest as important predisposing factors for cardiovascular susceptibility. This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI. MATERIAL/METHODS: We selected 458 patients with coronary heart disease undergoing PCI, and the genotype of CYP2C19*2 was detected by TaqMan real-time PCR. We finally enrolled 212 patients and divided them into 4 groups: a standard anti-platelet group of 46 patients, a clopidogrel double-dose group of 50 cases, a clopidogrel combined with tongxinluo group of 59 cases, and a ticagrelor group of 57. The platelet inhibition rate was detected by TEG. We analyzed and compared differences in platelet activity and the occurrence of MACE events in these 4 groups at different follow-up times. RESULTS: The results showed that inhibition of platelet aggregation was better in the double-dose clopidogrel group, the clopidogrel combined with tongxinluo group, and the ticagrelor group than in the regular-dose clopidogrel group, and ticagrelor was the best. We also found that the total incidence of MACE was much lower in the double-dose clopidogrel group, the clopidogrel combined with tongxinluo group, and the ticagrelor group, while the incidence of hemorrhage in the ticagrelor group was higher. CONCLUSIONS: Adjusting the dose or combining with other drugs improves the efficacy of anti-platelet therapy and reduces the incidence of ischemic events after PCI.
format Online
Article
Text
id pubmed-5555704
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-55557042017-08-17 Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI) Chen, Shuxia Zhang, Yi Wang, Lili Geng, Yanping Gu, Jian Hao, Qingqing Wang, Hua Qi, Peng Med Sci Monit Clinical Research BACKGROUND: In recent years, genetic factors have attracted research interest as important predisposing factors for cardiovascular susceptibility. This study aimed to investigate the influences of dual-dose clopidogrel, clopidogrel combined with tongxinluo, and ticagrelor on the platelet activity and MACE events of patients with CYP2C19*2 gene function deficiency and poor clopidogrel response after PCI. MATERIAL/METHODS: We selected 458 patients with coronary heart disease undergoing PCI, and the genotype of CYP2C19*2 was detected by TaqMan real-time PCR. We finally enrolled 212 patients and divided them into 4 groups: a standard anti-platelet group of 46 patients, a clopidogrel double-dose group of 50 cases, a clopidogrel combined with tongxinluo group of 59 cases, and a ticagrelor group of 57. The platelet inhibition rate was detected by TEG. We analyzed and compared differences in platelet activity and the occurrence of MACE events in these 4 groups at different follow-up times. RESULTS: The results showed that inhibition of platelet aggregation was better in the double-dose clopidogrel group, the clopidogrel combined with tongxinluo group, and the ticagrelor group than in the regular-dose clopidogrel group, and ticagrelor was the best. We also found that the total incidence of MACE was much lower in the double-dose clopidogrel group, the clopidogrel combined with tongxinluo group, and the ticagrelor group, while the incidence of hemorrhage in the ticagrelor group was higher. CONCLUSIONS: Adjusting the dose or combining with other drugs improves the efficacy of anti-platelet therapy and reduces the incidence of ischemic events after PCI. International Scientific Literature, Inc. 2017-08-07 /pmc/articles/PMC5555704/ /pubmed/28783717 http://dx.doi.org/10.12659/MSM.903054 Text en © Med Sci Monit, 2017 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Clinical Research
Chen, Shuxia
Zhang, Yi
Wang, Lili
Geng, Yanping
Gu, Jian
Hao, Qingqing
Wang, Hua
Qi, Peng
Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title_full Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title_fullStr Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title_full_unstemmed Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title_short Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI)
title_sort effects of dual-dose clopidogrel, clopidogrel combined with tongxinluo capsule, and ticagrelor on patients with coronary heart disease and cyp2c19*2 gene mutation after percutaneous coronary interventions (pci)
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555704/
https://www.ncbi.nlm.nih.gov/pubmed/28783717
http://dx.doi.org/10.12659/MSM.903054
work_keys_str_mv AT chenshuxia effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT zhangyi effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT wanglili effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT gengyanping effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT gujian effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT haoqingqing effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT wanghua effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci
AT qipeng effectsofdualdoseclopidogrelclopidogrelcombinedwithtongxinluocapsuleandticagreloronpatientswithcoronaryheartdiseaseandcyp2c192genemutationafterpercutaneouscoronaryinterventionspci